Skip to content

Prof. Stephen Chan

269
Prof. Stephen Chan
陳林教授
Share
qualifications
MBBS (HK), MD (CUHK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond)
rank
Ip’s Family Trust Professor of Clinical Oncology
Director, Office of Global Engagement, Faculty of Medicine
Assistant Dean (External Affairs), Faculty of Medicine
orcid
0000-0001-8998-5480
email
chanlam_stephen@cuhk.edu.hk

Specific Research / Sites of Interest

Clinical and translational researches on hepato-pancreatobiliary cancers and neuroendocrine tumours

Short Biography

Professor Chan is currently the clinical professor at the Department of Clinical Oncology of The Chinese University of Hong Kong.

Prof. Chan graduated from the University of Hong Kong and received the gold medal dissertation award and young investigator award by the Hong Kong College of Physicians.

Over the past 20 years, Prof. Chan has dedicated his time on advancing the clinical management of hepatobiliary, pancreatic and neuroendocrine tumours via clinical trials and scientific researches. He published over 270 papers in peer reviewed journals.

Prof. Chan is active both locally and internationally with leadership positions including


  • Associate Editor, Journal of Hepatology (IF 40.1 in 2025)

  • President, Executive Committee, the International Liver Cancer Association (ILCA)

  • Board Director of the CUHK Medical Centre

  • Founding Chair, the Hand-in-Hand cancer foundation, Hong Kong


Most Representative Publications

1. Chan, S.L., Ryoo, B.Y., Mo, F., Chan, L.L., Cheon, J., Li, L., Wong, K.H., Yim, N., Kim, H., Yoo, C. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024 Aug;81(2):258-264.
2. Lau, G., Abou-Alfa, G.K., Cheng, A.L., Sukeepaisarnjaroen, W., Dao, T.V., Kang, Y.K., Thungappa, S.C., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J.W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Azevedo, S., Reig, M., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Gupta, C., Negro, A., Chan, S.L. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol. 2025 Feb;82(2):258-267.
3. Kwong, T.T., Xiong, Z., Zhang, Y., Wu, H., Cao, J., Wong, P.P.C., Liu, X., Wang, J., Wong, C.H., Tse, G.M.K., Sung, J.J.Y., Zhou, J., Cheng, A.S.L., Chan, S.L. Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling. Mol Ther. 2025 Apr 2;33(4):1659-1673.
4. Rimassa, L#., Chan, S.L.#, Sangro, B., Lau, G., Kudo, M., Reig, M., Breder, V., Ryu, M.H., Ostapenko, Y., Sukeepaisarnjaroen, W., Varela, M., Tougeron, D., Crysler, O.V., Bouattour, M., Van Dao, T., Tam, V.C., Faccio, A., Furuse, J., Jeng, L.B., Kang, Y.K., Kelley, R.K., Paskow, M.J., Ran, D., Xynos, I., Kurland, J.F., Negro, A., Abou-Alfa, G.K. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025 Apr 11:S0168-8278(25)00226-0. (#equal contribution)
5. Chan, L.L., Chan, A.W.H., Yip, T.C.F., Wong, G.L.H., Ngai, A.K.H., Mo, F., Chok, S.H., Kung, J.W.C., Chu, C.M., Mok, K., Li, M.S.C., Wong, V.W.S., Chan, S.L. Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. J Hepatol. 2025 Jun 9:S0168-8278(25)02266-4.
6. Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klumpen, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine. 2018; 379 (1): 54-63.
7. Chan, S.L., Yeo, W., Mo, F., Chan, A.W., Koh, J., Li, L., Hui, E.P., Chong, C.C.N., Lai, P.B.S., Mok, T.S.K., Yu, S.C. A Phase 2 Study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017; 123(20): 3977-3985.
8. Chan, A.W., Kumada, T., Toyoda, H., Tada, T., Chong, C.C., Mo, F.K., Yeo, W., Johnson, P.J., Lai, P.B., Chan, A.T., To, K.F., Chan, S.L. Integration of albumin-bilirubin (ALBI) score into Barcelona clinic liver cancer (BCLC) system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 2016; 31(7): 1300-1306.
9. Chan, S.L., Mo, F., Johnson P., Li, L., Tang, N., Loong, H., Chan, A.W.H., Koh, J., Chan, A.T.C., Yeo, W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology. 2015; 30(10):1529-35.
10. Chan, S.L., Mo, F., Johnson, P.J., Siu, D.YW., Chan, M.H.M., Lau, W.Y., Lai, P.B., Lam, C.W.K., Yeo, W. Yu, S.C. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 2014; 16(4): 366-372.